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Modified release of furosemide from Eudragits® and 
poly(ethylene oxide)-based matrices and dry-coated tablets
Modified release of furosemide from tablet formulations is 
preferred by patients, because of physiological problems, 
acute diuresis being the most serious, compared to the 
forms designed for immediate release. With this in view, 
we aimed at achieving furosemide’s longer gastric reten-
tion and waste minimization by preparing matrix and 
compression coated tablets incorporating different grades 
of Eudragit® and poly(ethylene oxide) (PEO), polyvinylpyr-
rolidone (PVP) and lactose monohydrate. Dissolution pro-
files of the new formulations were compared with that of 
the main stream drug Lasix®, 40 mg tablets. The results 
indicate that the use of Eudragit® in conjunction with either 
PVP or lactose monohydrate led to a slower release rate in 
the intestinal fluids compared to Lasix®. Moreover, furose-
mide release in the intestinal pH from matrix tablets and 
compression coated tablets was not noticeably different. 
Formulations incorporating PEO led to sustained release, 
in intestinal fluids, which depended on the molecular 
weight of PEO.
Keywords: matrix tablets, compression coated tablets, furose-
mide, Eudragit®, poly(ethylene oxide), polyvinylpyrrolidone
Furosemide is widely used as a loop diuretic for the treatment of fluid retention (edema) 
of various origins, such as heart failure or kidney disease or high blood pressure. It is con-
sidered as the first line agent in people with edema caused by congestive heart failure and 
is the most commonly applied loop diuretic every year in the USA (1). Loop diuretics act 
at the ascending loop of Henle in the kidney and in contrast to thiazide diuretics, they are 
effective in patients with kidney diseases. More specifically, furosemide acts on the Na+/
K+/2Cl– co-transporter in the thick ascending limb of the loop of Henle and inhibits re-ab-
sorption of sodium, chloride and potassium (2). Also, furosemide exhibits a weak carbonic 
anhydrase-inhibiting activity and increases urinary excretion of HCO3– and phosphate (3).
Furosemide bioavailability is variable (10–90 %) and can be improved when it is taken 
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(4). Duration of its action is about 6 hours in case of oral administration and 2 hours when 
given intravenously. Furosemide is a week acid (pKa = 3.9), poorly soluble in the upper 
gastrointestinal tract, but it has high permeability through the stomach and is categorized 
as Class IV in the biopharmaceutical classification system. Many studies have been per-
formed concerning the solubility of furosemide. Its aqueous solubility is dependent on the 
pH of the medium, ranging from 0.18 mg mL–1, at pH 2.3, to 13.36 mg mL–1, at pH 10. Due 
to the pH-dependent solubility of furosemide, its absorption in humans is site-specific and 
takes place primarily in the upper parts of the small intestine (5). Researchers have already 
tried to increase its solubility by incorporating furosemide into cyclodextrins and by using 
some other novel drug delivery systems, like self microemulsifying drug delivery systems 
(SMEDDS), microparticles, Intelsite capsules, etc. (6–9). However, with its entrance into 
intestinal fluids, the drug releases rapidly from the currently used formulations, with a 
high peak of natriuretic and diuretic effect that causes displeasure to patients. This rapid 
release at the intestinal pH is due to the ionization of its carboxylic acid group. As a result, 
slower and more controllable intestinal release formulations are preferred because of a 
lower initial diuretic effect and a more extended duration of action.
In the last years, researchers have tried to develop a sustained release system of furo-
semide in order to improve the effectiveness of the drug. They have compared the effi-
ciency of immediate release with modified release systems of furosemide for decreasing 
the fluid (edema) in the thoracic cavity (10). To this end, carbopol and sodium alginate were 
used and the results indicated that carbopol can extend the release of furosemide (11). Dif-
ferent viscosity grades of hydroxypropylmethyl cellulose (HPMC), microcrystalline cellu-
lose and polyethylene glycol have also been used as excipients (12). Moreover, scientists 
have described the preparation and characterization of solid dispersions of furosemide 
with Eudragit® L100-55 (13), Eudragit® RL and RS, achieving controlled dissolution profiles 
with different carrier concentrations (14).
We have previously reported on the development of modified release formulations 
containing active substances of diverse chemical structures and physicochemical proper-
ties (15–21). Aiming at optimal delivery of furosemide, in order to provide more effective 
therapy, devoid of high peak natriuretic and diuretic adverse effects, its modified release 
profile from matrix and compression coated tablets is presented herein. Dry-coated tablets 
have all the advantages of compressed matrix tablets (e.g., slotting, monogramming, speed 
of disintegration, etc.). Moreover, they are used to separate incompatible drug substances 
(one in the core and the other in the coat) and can provide a means of giving an enteric 
coating to core tablets; in contrast to compressed matrix tablets, dry-coated tablets can 
deliver the drug in a pulsatile fashion. More importantly, polymers in compression coating 
can serve as sustained release agents (22 and references cited therein). In this study, matrix 
and compression coated tablets, incorporating different grades of Eudragit® polymers and 
poly(ethylene oxide, PEO) (PolyoxTM), polyvinylpyrrolidone and lactose monohydrate were 
used. These excipients are commonly used for oral administration and can be easily formu-
lated into matrix systems when it is required to modify the drug release rate from the 
solid dosage form. The different Eudragit® grades offer a great variety of physicochemical 
properties, depending on the release rate desired. We previously used PEO for the release of 
furosemide from hard gelatin capsules and the results showed that the low molecular weight 
polymers have a less extended sustained-release effect compared to the high molecular 
weight poly(ethylene oxide) (23).
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Furosemide was purchased from Sigma-Aldrich (Steinheim, Germany). The different 
grades of Eudragit® polymers L 100-55, L100, S100, RL100, RS were purchased from Rohm 
GmbH Pharma Polymers (Darmstadt, Germany). Poly(ethylene oxide) (Mr 0.9 × 106, 4 × 106, 
5 × 106, 7 × 106), polyvinylpyrrolidone (PVP, average MW 10.000), and Sodium Lauryl 
Sulfate (SLS) were purchased from Sigma-Aldrich (Steinheim, Germany), lactose mono-
hydrate was purchased from Merck, whereas magnesium stearate was obtained from 
Riedel-De Haen (Hannover, Germany). Lasix® 40 mg tablets are commercially available 
and were purchased from a local drug store. All chemicals were of reagent grade and were 
used in the study without further purification.
Methods
Preparation of Furosemide matrix and dry coated tablets
Each matrix tablet (formulations F1-F10 and F16-F28) comprised furosemide (60 mg) 
and combinations of the following excipients: different grades of Eudragit® polymer, PVP, 
lactose monohydrate, poly(ethylene oxide), SLS and magnesium stearate (as a lubricant). 
All the components (except for the lubricant) were blended in a mixing apparatus (Wab 
Turbula Type T2F) for 10 min (32 rpm). Magnesium stearate was then added to the mixture, 
which was blended for another 5 min. Total weight of each tablet was 200 mg, regardless 
of the composition, and tablets were produced using a 10 mm diameter die and a hydraulic 
press (Massen type, MP 150).
Formulations F11-F15 refer to dry coated tablets. The coating mixture comprised com-
binations of different grades of Eudragit® polymers with PVP and magnesium stearate as 
Table I. Tablet composition of formulations F1-F15
Formula-
tion (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15
Matrix tablets Dry coated tablets
Furosemide 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60
Eudragit® 
 
L100-55 70 – – – – 70 – – – – 70 – – – –
L100 – 70 – – – – 70 – – – – 70 – – –
S100 – – 70 – – – – 70 – – – – 70 – –
RL100 – – – 70 – – – – 70 – – – – 70 –
RS100 – – – – 70 – – – – 70 – – – – 70
Lactose 68 68 68 68 68 – – – – – – – – – –
PVP 10,000 – – – – – 68 68 68 68 68 68 68 68 68 68
Mg Stearate 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Total 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200
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a lubricant. Components of the coating mixture (except for magnesium stearate) were 
blended in a mixing apparatus for 10 min and then magnesium stearate was added to the 
mixture, which was blended for another 5 min. The core of the tablets comprised Furose-
mide (60 mg) and magnesium stearate, and was formed using a 7.5 mm diameter die and 
hydraulic press (Massen type, MP 150). The core was placed in a 10 mm diameter die and 
the coating mixture (140 mg) was added. The final tablet was produced using a hydraulic 
press. Tables I and II illustrate the composition of tablets in each formulation.
Tablet uniformity tests
All tablets were evaluated for mass, hardness, thickness, drug content uniformity and 
friability.
Mass uniformity. – Twenty tablets or compression-coated tablets from each formulation 
were weighed individually using an electronic pan balance. The weight of each tablet was 
compared with the respective average weight of the tablets.
Crushing strength. – Crushing strength of tablets was determined using a hardness 
tester (Erweka, type TBH28) and the average value of three determinations was reported. 
Hardness strength is expressed in N (63.55–122.81 N).
Thickness. – Tablet thickness was measured with a Vernier caliper and the average of 
three determinations was calculated.
Friability. – Friability of the tablets was determined using a friabilator (Erweka, type 
TA3R). Percent friability is reported in terms of weight loss and has been calculated as 
percentage of the initial weight, according to Pharmacopeia specifications. Initial mass 
(W0) of 33 tablets was weighed and put into a drum rotating at a rate of 25 rpm for 4 min. 
Tablets were then carefully dedusted with a soft brass deduster and reweighed (WR). Per-
cent friability of the tablets was calculated using the following Eq. (1):
Table II. Tablet composition of formulations F16-F23
Formulation (mg) F 16 F 17 F 18 F 19 F 20 F 21 F 22 F 23
Furosemide 60 60 60 60 60 60 60 60
Eudragit® L100 70 70 70 – – – – –
Lactose 40 34 28 – – – – –
PVP 10.000 28 34 40 – – – – –
PolyoxTM 0.9 × 106 – – – 138 – – – 134
PolyoxTM 4 × 106 – – – – 138 – – –
PolyoxTM 5 × 106 – – – – – 138 – –
PolyoxTM 7 × 106 – – – – – – 138 –
SLS – – – – – – – 4
Mg Stearate 2 2 2 2 2 2 2 2
Total 200 200 200 200 200 200 200 200
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  (1)
Drug content uniformity. – Three tablets from each batch were crushed in a glass mortar 
and dissolved singly in 100 mL sodium hydroxide in a stoppered conical flask, which was 
shaken in a mechanical shaker for 4 h. The samples were filtrated through a membrane 
filter and assayed for drug concentration using a Perkin-Elmer UV spectrophotometer 
(Norwalk, CT) at a wavelength of 274 nm. Calculation of drug content for each tablet was 
made using the standard curve. The percent of the label claim was used in the expression 
of the drug content for each tablet. Drug content not less than 90 and not more than 110 % 
of the active substance was considered acceptable (24).
Dissolution studies
The in vitro dissolution tests of the tablets were performed using a USP XXII dissolu-
tion apparatus II (Pharmatest Hainerp, Germany) (paddle method). Dissolution medium 
for the first 2 hours was 450 mL of a buffer solution pH 1.2 (HCl solution 0.2 mol L–1) in 
order to simulate the stomach pH and then 450 mL of a buffer dissolution pH 9 (K2HPO4 
solution, 0.14 mol L–1) was added to obtain the required composition of the following 
phase, which simulated the enteric pH (pH 6.8, final volume 900 mL). The system was 
maintained at a controlled temperature of 37.0 ± 0.5 oC and the paddles were rotated at a 
rate of 50 rpm. Samples (5 mL) were taken at predetermined time intervals and passed 
through a 0.45 μm cellulose filter. At each time point, the volume was refilled with an equal 
volume of fresh medium. The concentration of furosemide released into the medium was 
measured using a Perkin-Elmer UV spectrophotometer (Norwalk, CT) at a wavelength of 
274 nm and 234 nm when the dissolution medium was pH 1.2 and pH 6.8, respectively.
In order to compare the dissolution profiles of the formulation, graphs of the percent 
drug release vs. time were constructed and t20%, t50%, t90% values were estimated. The t20%, 
t50%, t90% values refer to the time when 20, 50 and 90 % of the active substance was released. 
The dissolution efficiency (D.E.) percent, a parameter used to estimate dissolution, was 
calculated according to the following Eq. (2) (25):
  (2)
where y is the percentage of dissolved product, D.E. is the area under the dissolution curve 
between time points t1 and t2, expressed as percentage of the curve at a maximum dissolu-
tion y100 over the same period.
Finally, the in vitro release data were fitted to the Korsmeyer-Peppas Eq. 3 (26, 27):
  (3)
where  is the percentage of the drug substance released, k is the release rate constant, t is 
the release time and n is the diffusion coefficient. This equation is valid for the first 60 % 
of fractional release. The n values represent either Fickian or non-Fickian release kinetics. 
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In particular, in the case of cylindrical tablets, n > 0.45 corresponds to Fickian diffusion 
release (Case I diffusion), 0.45 < n < 0.89 to anomalous transport, n = 0.89 to zero order (Case 
II) and n > 0.89 to Super Case II release kinetics (28, 29).
RESULTS AND DISCUSSION
Tablet uniformity tests
Uniformity of mass. – Mass uniformity is used to evaluate the uniformity of formula-
tions. Results in Table III indicate the value for weight deviation of < 1 %, which is signifi-
Table III. Results of uniformity tests: average mass expressed, crushing strength, thickness expressed, % 




















Mean ± SD 
(n = 3)1
Lasix® 161.6 ± 0.3 70.08 ± 1.23 2.3 ± 0.0 0.11 101.32 ± 0.78
F1 200.2 ± 0.8 120.69 ± 1.34 1.97 ± 0.6 0.12 100.78 ± 0.34
F2 200.4 ± 0.9 109.57 ± 0.56 1.8 ± 0.0 0.11 100.44 ± 0.62
F3 200.5 ± 0.7 72.77 ± 1.09 1.8 ± 0.0 0.69 102.56 ± 0.42
F4 200.3 ± 0.2 63.55 ± 0.39 1.8 ± 0.0 0.72 101.64 ± 0.31
F5 200.8 ± 0.7 72.28 ± 1.06 1.9 ± 0.0 0.78 100.37 ± 0.62
F6 200.1 ± 0.4 111.08 ± 2.21 1.9 ± 0.0 0.18 99.46 ± 0.84
F7 200.7 ± 0.4 88.06 ± 1.03 2.0 ± 0.0 0.44 101.12 ± 0.55
F8 200.9 ± 0.9 84.27 ± 1.50 2.0 ± 0.0 0.42 101.27 ± 0.61
F9 200.2 ± 0.1 65.87 ± 0.89 2.0 ± 0.0 0.72 100.36 ± 0.47
F10 200.3 ± 0.8 67.93 ± 0.83 2.0 ± 0.0 0.67 101.54 ± 0.63
F11 200.5 ± 0.8 103.56 ± 0.98 2.0 ± 0.0 0.14 101.3 ± 0.16
F12 200.2 ± 0.7 110.06 ± 0.98 2.0 ± 0.0 0.12 100.42 ± 0.18
F13 200.3 ± 0.2 98.00 ± 1.85 2.0 ± 0.0 0.18 100.61 ± 0.75
F14 200.7 ± 0.8 94.63 ± 0.45 1.9 ± 0.0 0.16 101.41 ± 0.71
F15 200.2 ± 0.8 96.82 ± 0.63 2.0 ± 0.0 0.19 101.24 ± 0.63
F16 200.8 ± 0.5 101.14 ± 0.99 2.0 ± 0.0 0.27 99.26 ± 0.13
F17 200.6 ± 0.7 102.61 ± 0.54 1.97 ± 0.6 0.24 101.29 ± 0.24
F18 200.2 ± 0.4 96.86 ± 0.50 2.0 ± 0.0 0.18 100.24 ± 0.18
F19 200.6 ± 0.5 122.81 ± 0.15 1.97 ± 0.6 0.17 102.37 ± 0.21
F20 200.2 ± 0.6 89.93 ± 0.26 1.97 ± 0.6 0.22 101.36 ± 0.44
F21 200.7 ± 0.8 119.28 ± 1.85 2.0 ± 0.0 0.18 100.32 ± 0.37
F22 200.3 ± 0.9 101.76 ± 1.13 1.97 ± 0.6 0.23 100.33 ± 0.58
F23 200.2 ± 0.1 67.60 ± 0.83 2.0 ± 0.0 0.78 101.1 ± 0.46
1 n – the number of tested tablets
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cantly less than ± 7.5 % from the official standard. As a result, all tablets passed the pharma-
copeia requirements for weight variation (30).
Crushing strength. – Crushing strength test shows the ability of tablets to withstand 
pressure or stress during handling, packaging and transportation. The results (Table III) 
indicate that the maximum breaking force is within the acceptable crushing strength 
range (63.55–122.81 N) (31).
Thickness. – Thickness uniformity is used to evaluate the uniformity of formulations. 
Using the Vernier caliper method, employed in scientific laboratories and in manufacturing, 
the results shown in Table III indicate an acceptable value for thickness deviation of < 1 %.
Friability. – Results of tablet friability tests show that all the formulations had friability 
values ranging from 0.11 to 0.78 % (m/m) (Table III). According to USP, no formulation 
should have a friability value higher than 1.0 % (m/m); therefore, all formulations passed 
the test.
Drug content uniformity. – Results obtained from the assessment of the percent content 
of active ingredients in all furosemide formulations showed values within the USP mono-
graph specifications (90–110 %) (Table III).
Table III illustrates the results of uniformity tests: average mass, crushing strength, 
thickness, percent friability and drug content.
Dissolution studies
To assess dissolution profiles, dissolution curves of the formulations were constructed 
and are depicted in Fig. 1.
Fig. 1. Furosemide % release (mean values ± SD, n = 3) vs. time (min) from formulations: a) 1–10, b) 
6–15, 2, 7, c) 16–18, d) 19–23 at pH 1.2 (0–2 h), at pH 6.8 (120–480 min).
a)                                                                             b)
c)                                                                             d)
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Table IV illustrates the kinetic properties of drug release for Lasix® and the produced 
formulations. Terms t20%, t50%, and t90% refer to the time when 20, 50 and 90 % of the dis-
solution is completed, respectively.
Fig. 1 illustrates the profile of furosemide release from the new formulations, which 
is compatible with both the gastroretentive and slower intestinal release requirements, 
with a well-defined absorption window. Precisely, at pH 6.8, the new formulations, which 
involve the pH dependant, water soluble polymers, Eudragit® L100-55, L100 and S100, per-
mit facile water penetration into the tablet and consequently hydration of the formulation 
system leading to sustained drug dissolution. On the other hand, the use of water swellable 
polymers, Eudragit® RL and RS, which are not pH dependant, leads to lower release (Figs. 
1a and 1b) (D.E. of F4 = 37.45 and F5 = 33.15 vs. F1 = 43.05, F2 = 54.69, F3 = 42.88). Analogous 
results were obtained by other researchers (32, 33).
Lactose is a water soluble excipient and has the potential to act as an agent that facili-
tates diffusion of the active substance from the hydrophilic polymeric matrix, since it leads 
to a more rapid relaxation of polymer chains. Therefore, lactose is considered one of the 
most suitable excipients used to accelerate the release of the active ingredient from con-
trolled release systems from the hydrophilic polymer matrices (34). Substitution of lactose 
by PVP augmented the release of furosemide at pH 6.8 (Fig. 1a) (D.E. of F1 = 43.04 vs. F6 = 
49.84 and F3 = 42.88 vs. F8 = 48.72). This PVP-owed furosemide percent release enhance-
ment is in agreement with a recent literature report (35). A plausible explanation is that, at 
pH 1.2, protonation of the anilino-nitrogen of furosemide is preferable to -CO2H proton-
ation, even though the proximity of the amine and acid groups seems to allow a simultane-
ous interaction of the proton with both groups, thus stabilizing and delocalizing the 
charge more effectively (structures A and B) (Fig. 2) (36). With respect to PVP, it exists in 
the gem-diol form in the acidic medium (III, Fig. 3) (21), which does not facilitate furose-
mide dissolution, since H-bond formation between the OH of the diol and the anilino-ni-
trogen atom of furosemide is not feasible due to aryl-NH protonation (structure A).
Conversely, in neutral pH aqueous medium, H-bond formation is feasible between the 
oxygen atom of PVP (resonance structure II) and the aryl-NH hydrogen atom (structure B, 
Fig. 2), leading to the observed enhanced aqueous solubility of furosemide.
Fig. 1b illustrates the comparison of drug release from matrix and dry-coated tablets. 
It is observed that when the pH changes from acidic to neutral, at 120 min, the coating in 
Fig. 2. a) Amine-protonated form of furosemide and b) the carboxylic acid-protonated form of furo-
semide.
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formulations F14 and F15, consisting of Eudragit® RL-100, RS-100 and PVP, enhances the 
release of furosemide from the dry-coated tablets. Conversely, the coating in formulations 
F11, F12 and F13, consisting of Eudragit® L100-55, L-100 S-100 and PVP retards the release 
of furosemide from the dry-coated tablets (D.E. of F14 = 63.39, F15 = 58.22 vs. F11 = 35.41, 
F12 = 44.45, F13 = 50.85). Release of furosemide from matrix tablets containing the respec-
tive excipients (F6, F7 and F8) is generally higher. Release of the drug from the matrix 
tablets (F9 and F10) containing Eudragit® RL-100, RS-100 and PVP is lower than that from 
formulations F6-F8, (D.E. of F9 = 42.05, F10 = 37.61), F9 showing zero order kinetics (n = 0.90, 
Table IV. Kinetic properties of drug release for Lasix® and the produced formulations
Formulation t20% t50% t90% D.E. n
Lasix® 15 125 170 79.36 0.13
F1 155 218 > 480 43.04 1.19
F2 125 162 > 480 54.69 3.29
F3 150 205 > 480 42.88 0.57
F4 158 265 > 480 37.45 0.78
F5 160 314 > 480 33.15 0.77
F6 152 212 420 49.84 1.08
F7 148 204 390 52.22 1.37
F8 148 213 448 48.72 0.83
F9 155 260 > 480 42.05 0.90
F10 167 284 > 480 37.61 0.98
F11 196 276 > 480 35.41 1.15
F12 193 250 421 44.45 1.18
F13 180 236 310 50.85 2.71
F14 140 172 225 63.39 –a
F15 155 200 262 58.22 –
F16 144 188 242 60.69 –
F17 144 184 239 61.35 –
F18 141 176 248 62.06 –
F19 147 228 456 45.17 0.81
F20 172 342 > 480 31.56 0.92
F21 176 404 > 480 26.98 0.98
F22 197 > 480 > 480 23.59 0.89
F23 162 282 455 40.43 1.32
D.E. – dissolution efficiency; n – diffusion coefficient estimated by the Korsmeyer-Peppas equation (Eq. 3). 
a n values could not be calculated (release > 60 %).
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Table IV). The release mechanism of furosemide from the dry-coated tablets in all cases 
corresponds to Super Case II release kinetics (n > 0.89) (Table IV).
When PVP and lactose were combined in different ratios into matrix systems, the 
drug dissolution increased in all cases, compared to the cases when these excipients were 
separately used (D.E. of F16 = 60.69, F17 = 61.35, F18 = 62.06, vs. F2 = 54.69, F7 = 52.22), (Fig. 
1c, Table IV). This is probably due to the synergistic effect of PVP, which, as previously 
mentioned, exists at pH 6.8 in the ionic structure II form (Fig. 3), thus enhancing the over-
all ionic character of the lactose/PVP mixture.
Use of various molecular weight poly(ethylene oxide) results in different release rates, 
and this does not seem to be drastically affected by the presence or absence of the SLS 
surfactant (D.E. of F19 = 45.17, F23 = 40.43) (Fig. 1d, Table IV). It is well known that the 
lower the molecular weight, the greater is the drug release rate (37) (D.E. of F19 = 45.17, F20 
= 31.56, F21 = 26.98, F22 = 23.59). Drug release from the low molecular weight poly(ethylene 
oxide) is strictly related to the polymer dissolution mechanism, while drug release from 
the high molecular weight poly(ethylene oxide) is principally related to material swelling 
and not to polymer dissolution (37). The drug release mechanism, when low molecular 
weight poly(ethylene oxide) (0.9 × 106) is used, corresponds to anomalous transport (n = 
0.81). When higher molecular weight poly(ethylene oxide) (4 and 5 × 106) is used, the drug 
release kinetics corresponds to Super Case II (n > 0.89). When poly(ethylene oxide) molecu-
lar weight (7 × 106) is used, the release of furosemide becomes zero order (n = 0.89, Case II).
Fig. 3. PVP (I) conversion to gem-diol (III) (16).
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CONCLUSIONS
In general, the combinations of excipients used in this study, when compressed into 
matrix or dry-coated tablets, promoted modified release of furosemide in gastrointestinal-
like environments. Release of furosemide from the systems examined in this study was 
found to be controllable and compatible with both the gastroretentive and slower intesti-
nal release requirements, with a well-defined absorption window. The type of tablets af-
fected both drug release and release mechanisms. These findings will be useful in the 
future in vivo studies.
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